Chemed Corp (CHE) · Oct 27, 2026 · Earnings

Chemed Q3 earnings beat as VITAS surges, Roto-Rooter slips

Beat — Adjusted EPS $6.75 vs ~$6.39 consensus; revenue $690.9M vs ~$685.0M

Chemed’s Q3 earnings beat consensus on accelerating VITAS growth, while Roto-Rooter revenue rose but profitability weakened and guidance reached its high end.

Chemed is navigating a clear split: VITAS is accelerating after last year’s Medicare Cap disruption, while Roto-Rooter is growing revenue but struggling to convert that growth into profit. Management had already raised full-year 2026 adjusted EPS guidance in July, mainly because VITAS was outperforming expectations, while Roto-Rooter was described as broadly in line.

MetricQ3 2026Q3 2025Change / comparison
Revenue$690.9M$624.9M+10.6%; versus ~$685.0M consensus
GAAP diluted EPS$5.45$4.46+22.2%
Adjusted diluted EPS$6.75$5.27+28.1%; versus ~$6.39 consensus
VITAS net revenue$457.4M$407.7M+12.2%
VITAS adjusted EBITDA, excluding Medicare Cap$92.5M—+31.4%; margin 20.2%, up 318 bps
Roto-Rooter revenue$233.5M$217.2M+7.5%
Roto-Rooter adjusted EBITDA$48.2M—-2.5%; margin down 213 bps

VITAS is the real earnings driver, and the improvement was better than merely a Medicare Cap comparison. Net patient revenue rose 12.2%, with days of care up 9.4% and admissions up 7.2%; the company also recorded only $828,000 of Medicare Cap limitation versus $6.1 million a year earlier. The result was a 31.4% increase in adjusted EBITDA excluding Medicare Cap and a 318-basis-point margin expansion, showing that volume growth and lower cap pressure are flowing through to profitability.

The quarter beat consensus, but the beat was concentrated rather than broad-based. Adjusted EPS of $6.75 exceeded the published consensus of roughly $6.39, while revenue of $690.9 million was modestly ahead of roughly $685.0 million. The earnings upside came primarily from VITAS; Roto-Rooter revenue grew 7.5%, but adjusted EBITDA fell 2.5% as SG&A rose 17.1% and its margin declined to 20.6%.

Roto-Rooter is investing through weakness, which adds future capacity but also raises execution risk. The company spent approximately $62.5 million reacquiring California franchise territories covering more than 12 million people, with new branches planned in Sacramento and San Diego. That expands the owned operating footprint, but the quarter shows the near-term cost: revenue growth has not yet translated into operating leverage.

The outlook improved qualitatively, but not with a formal new range. Chemed said it expects to be “at or slightly above” the high end of its existing full-year adjusted EPS guidance, which was previously $25.00–$25.75. This is better than the standing assumption, but the absence of a precise new range leaves the magnitude of the upgrade for the October 28 conference call. 〔0〕

Bottom line: This is a genuine earnings beat and a further validation of VITAS’s recovery, not just a favorable comparison against last year’s Medicare Cap burden. The business is improving overall, but Roto-Rooter’s falling margins and California expansion mean the next phase depends on turning revenue growth into profit.

What to watch next

October 28 earnings call and operational outlook

Original filing on SEC EDGAR

Chemed Q3 earnings beat as VITAS surges, Roto-Rooter slips | CHE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.